<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014586</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-30991</org_study_id>
    <secondary_id>EORTC-GU-30991</secondary_id>
    <nct_id>NCT00014586</nct_id>
  </id_info>
  <brief_title>Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>Randomized Phase III Step-Up Study On Initial Antiandrogen Monotherapy In Comparison With Watchful Waiting In Asymptomatic T1-3 Any G (Any Gleason) NO or Nx M0 Prostate Cancer Patients Without Local Treatment With Curative Intent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Testosterone can stimulate the growth of cancer cells. Bicalutamide and goserelin&#xD;
      may fight prostate cancer by reducing the production of testosterone. It is not yet known&#xD;
      which hormone therapy regimen is most effective for prostate cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of bicalutamide with that of&#xD;
      observation followed by bicalutamide plus either goserelin or orchiectomy for patients who&#xD;
      have prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the overall and cancer-specific survival of patients with prostate cancer&#xD;
           treated with bicalutamide alone followed by bicalutamide with either goserelin or&#xD;
           bilateral orchiectomy vs observation followed by bicalutamide with either goserelin or&#xD;
           bilateral orchiectomy.&#xD;
&#xD;
        -  Compare the time to first and second clinical progression in patients treated with these&#xD;
           regimens.&#xD;
&#xD;
        -  Compare the quality of life, including potency, of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center, tumor differentiation grade (G3 or Gleason more than 6 vs other&#xD;
      values), T category, comorbidity (i.e., chronic disease) (yes vs no), potency (yes vs no),&#xD;
      type of chosen hormonal ablation (goserelin vs orchiectomy), PSA level (less than 10 ng/mL vs&#xD;
      10-20 ng/mL vs 20-100 ng/mL), and N status (N0 vs NX). Patients are randomized to one of two&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral bicalutamide once daily. At first symptomatic disease&#xD;
           progression, patients also receive goserelin subcutaneously once every 28 or 84 days or&#xD;
           undergo bilateral orchiectomy. At second disease progression, patients discontinue&#xD;
           bicalutamide.&#xD;
&#xD;
        -  Arm II: Patients are observed until first symptomatic disease progression. At first&#xD;
           disease progression, patients receive bicalutamide with either goserelin or bilateral&#xD;
           orchiectomy as in arm I. Patients discontinue bicalutamide as in arm I.&#xD;
&#xD;
      Quality of life is assessed at baseline, every 6 months for 6 years, at each disease&#xD;
      progression, and then annually thereafter.&#xD;
&#xD;
      Patients are followed annually.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 1266 patients (633 per treatment arm) will be accrued for&#xD;
      this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>January 2001</start_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">110</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>orchiectomy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed prostate cancer&#xD;
&#xD;
               -  T1-3, any G (any Gleason), N0 or NX&#xD;
&#xD;
          -  High risk defined as G3 or Gleason more than 6 or PSA more than 20 ng/mL and unfit or&#xD;
             unwilling to undergo local curative therapy OR&#xD;
&#xD;
          -  Low risk defined as G1-2 or Gleason less than 7 and PSA no more than 20 ng/mL and no&#xD;
             prior local curative therapy&#xD;
&#xD;
          -  Asymptomatic (pain score of 0)&#xD;
&#xD;
          -  PSA no more than 100 ng/mL (no more than 25 times normal)&#xD;
&#xD;
          -  No metastatic disease by chest x-ray, bone scan (if PSA more than 10 ng/mL or 2.5&#xD;
             times normal), and pelvic CT (if chance of lymph node metastases is at least 5% by&#xD;
             Partin tables)&#xD;
&#xD;
          -  No bone disease that would interfere with diagnosis of metastatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  80 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell skin&#xD;
             cancer&#xD;
&#xD;
          -  No psychological, personal, sociological, or geographical condition that would&#xD;
             preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald H.J. Mickisch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Center of Operative Urology Bremen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center of Operative Urology Bremen</name>
      <address>
        <city>Bremen</city>
        <zip>D-28277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

